Association between adjuvant tamoxifen treatment for breast cancer and subsequent cataract

陈　涵; 邵志敏; 余科达; 徐格致

doi:10.19401/j.cnki.1007-3639.2019.07.005

您当前的位置：

首页 >

文章列表页 >

Association between adjuvant tamoxifen treatment for breast cancer and subsequent cataract

更新时间：2026-01-27

- Association between adjuvant tamoxifen treatment for breast cancer and subsequent cataract
- China Oncology Vol. 29, Issue 7, Pages: 508-509(2019)
- 作者机构：
  
  1. 复旦大学附属眼耳鼻喉医院眼科,上海,200031
  2. 复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.07.005
  CLC： R737.9;R776.1
- Published Online：12 July 2019，
  
  Published：12 July 2019
- 稿件说明：
移动端阅览
陈　涵,邵志敏,余科达,徐格致 . 乳腺癌辅助他莫昔芬治疗与后续白内障发生的相关性分析[J]. 中国癌症杂志, 2019, 29(7): 508-509.

陈　涵, 邵志敏, 余科达, et al. Association between adjuvant tamoxifen treatment for breast cancer and subsequent cataract[J]. China Oncology, 2019, 29(7): 508-509.
陈　涵,邵志敏,余科达,徐格致 . 乳腺癌辅助他莫昔芬治疗与后续白内障发生的相关性分析[J]. 中国癌症杂志, 2019, 29(7): 508-509. DOI： 10.19401/j.cnki.1007-3639.2019.07.005.

陈　涵, 邵志敏, 余科达, et al. Association between adjuvant tamoxifen treatment for breast cancer and subsequent cataract[J]. China Oncology, 2019, 29(7): 508-509. DOI： 10.19401/j.cnki.1007-3639.2019.07.005.

摘要

背景与目的：他莫昔芬是绝经前激素受体阳性乳腺癌辅助内分泌治疗的标准药物，也是绝经后患者的重要选择。目前，他莫昔芬治疗与后续白内障发生的相关性争议较大，需进一步证实。方法：分析复旦大学附属肿瘤医院乳腺外科前瞻性维护的病例数据库中的相关信息，结合门诊随诊数据，共纳入3 034例可用患者。其中无内分泌治疗患者806例，含他莫昔芬治疗1 065例，仅接受芳香化酶抑制剂治疗1 163例。对无内分泌治疗与含他莫昔芬治疗两组，根据后续发生白内障与否进行关联分析，并进行年龄（≤40岁、40~50岁、＞50岁）与他莫昔芬用药时长（用药5年内、超过5年）的亚组研究。结果：无内分泌治疗组（806例）与含他莫昔芬治疗组（1 065例）两组间白内障发生率没有显著差异（HR=1.1，95% CI：0.8~1.5；P=0.70）。但在不同年龄亚组中有不同情况：≤40岁组与40~50岁组，他莫昔芬的使用与白内障发病没有显著关联；在＞50岁组，使用他莫昔芬后发生白内障的概率（15.4%）是未使用组（9.0%）的1.8倍（95% CI：1.1~3.1；P=0.024）。不仅如此，多因素分析揭示，长期使用他莫昔芬（超过5年）的患者也相对于5年内使用患者有更高的白内障发生风险。结论：虽然在整体人群中白内障与他莫昔芬无显著相关，但在中老年等绝经后患者及长时间他莫昔芬用药患者中，白内障的发病风险显著提高。提示选择他莫昔芬治疗时，要重视各类不良反应风险的评估和白内障高危人群的鉴别。

Abstract

Background and purpose: Tamoxifen is the standard adjuvant endocrine therapy for early premenopausal hormone receptor-positive breast cancer and an important choice for postmenopausal patients. At present

the relationship between tamoxifen treatment and subsequent cataract occurrence is controversial. Methods: The relevant cases from the prospectively maintained database of the Department of Breast Surgery in Shanghai Cancer Center were analyzed. Among 3034 patients

806 patients did not receive endocrine therapy

1065 patients were treated with tamoxifen

and 1 163 patients received aromatase inhibitor alone. For patients without tamoxifen treatment and those without endocrine therapy

association study was performed according to the age (≤40 years

41-50 years

50 years) and tamoxifen treatment time. Results: Although there was no significant difference in the incidence of cataract between the non-endocrine group (806 patients) and the tamoxifen-treated group (1 065 patients) (HR=1.1

95% CI: 0.8-1.5; P=0.70)

subgroup analyses according to the age showed different outcomes. In the ≤40 years and 40-50 years groups

tamoxifen was not significantly associated with cataract incidence. However

in the 50 years group

tamoxifen treatment led to a significantly higher risk of developing cataract with 1.8 times that of the unused group (15.4 % vs 9.0%

95% CI: 1.1-3.1; P=0.024). Moreover

multivariate analysis revealed that patients with long-term use of tamoxifen (more than 5 years) also had a higher risk of cataract than those with less than 5-year treatment of tamoxifen. Conclusion: Although the incidence of cataract was not significantly associated with tamoxifen use in the overall population

the risk of cataract was significantly increased in postmenopausal patients and those with long-term tamoxifen medication. When we select tamoxifen candidates

we should pay attention to the assessment of toxicity risk as well as cataract.

关键词

Keywords

references

Views

3393

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances in estrogen receptor low positive early breast cancer

Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer 2021 CACA-CBCS

Current status of adjuvant therapy for early stage breast cancer in China: a cross-sectional study based on 110 hospitals

中国早期乳腺癌卵巢功能抑制临床应用专家共识(2016年版)

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Related Author

Yizi JIN

Mingxi LIN

Cheng ZENG

Qing GUO

Jian ZHANG

Committee of Breast Cancer Society Chinese Anti-Cancer Association,

琪

瑢

Related Institution

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

中国医学科学院肿瘤医院肿瘤内科

复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰